Navigation Links
KaloBios to Present at Leerink Swann Rare Disease Roundtable
Date:9/30/2013

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company will present at the Leerink Swann Rare Disease Roundtable on October 2 at the Le Parker Meridien in New York City. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Company Presentation:
When: Wednesday, October 2, 2013, 10:30 AM EDT
Where: Le Parker Meridien, New York City, NY

Webcast:
To access the live and archived audio webcast of this presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab: http://leerink.metameetings.com/webcasts/rdroundtable13/directlink?ticker=KBIO.

A replay of the webcast will be available one hour after the conclusion of the live event. 

About KaloBios
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer.  For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

Contact:

Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
ir@kalobios.com

Media Contact:

Joan E. Kureczka
Kureczka/Martin Associates 
Tel:  (415) 821-2413
Mobile: (415) 690-0210
Joan@Kureczka-Martin.com


'/>"/>
SOURCE KaloBios Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
2. KaloBios Pharmaceuticals Completes Initial Public Offering
3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
8. KaloBios to Present at Needham Healthcare Conference
9. KaloBios Reports First Quarter 2013 Financial Results
10. KaloBios to Present at Stifel Healthcare Conference 2013
11. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 - ... in Personalized Medicine and Cancer Therapy. - European ... Diagnostic Testing Markets. - Key Diagnostic Testing Markets. ... Molecular Diagnostics in Genetic Testing. - Molecular Diagnostics ... - Over-the-Counter Diagnostic Products World Markets. - ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016  Kindred Biosciences, ... on saving and improving the lives of pets, today ... Section of the New Animal Drug Application (NADA) for ... pivotal field study (KB0120) of Zimeta for the control ... the Company. --> --> ...
(Date:2/11/2016)... -- NOIT™ Research LLC, a private, leading-edge autism research group, ... assist needy families in obtaining one of its special ... 10, 2016 and March 31, 2016, the company will ... is an auditory stimulus that plays a key role ... Beth Shier , NOIT Research director. "The ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... Sun City is the place to be on March 3rd to learn about the latest ... hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will be presented ... addition, prizes will be given away and light refreshments will be served. , As ...
(Date:2/13/2016)... ... ... Many individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased ... has delved into this niche allowing those giving up their beloved pasta a chance ... grams of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released ... visualization technology should be used to ensure patient safety when placing an IV ... Standards mandate the use of vein visualization technology in patients with difficult venous ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or ... groom themselves to perfection, go out of their way to be romantic, and may ... take a look at any online dating profile. , A recent study from ...
(Date:2/12/2016)... San Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... of love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. ... in fact a love story, the love of a Buddhist teacher for teaching and ...
Breaking Medicine News(10 mins):